Dr. Stefanie Aeppli
Medizinische Onkologie und Hämatologie · Dept. I
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
Jan 26, 2024
Clinical Studies - Jan 26, 2024 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Scherrer Julia, Quinter Janine
Keyvibe - MK7684A-010
Mar 24, 2023A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
Clinical Studies - Mar 24, 2023 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Sennhauser Andrina, Müller Fiona
Muscle-invasive bladder cancer (MIBC) and perioperative treatment
May 13, 2022Diese Studie untersucht die Kombination der Standardtherapie für das muskelinvasive Blasenkarzinom (Chemotherapie gefolgt von einer Operation mit Entfernung der Harnblase) mit einer Immuntherapie mit Bacille Calmette Guérin (BCG) und Atezolizumab. BC...
Clinical Studies - May 13, 2022 - May 13, 2032
Ongoing
Project leader: Aeppli Stefanie
Members: Scherrer Julia, Müller Fiona
A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS
Jul 17, 2020Multizentrische Studie bei Patienten mit metastasiertem Nierenzellkarzinom nach Progredienz unter einer Erstli-nientherapie mit ICI/ICI oder ICI/TKI Kombination zur Eva-luation der Wirksamkeit und Verträglichkeit des Tyrosin-kinase Inhibitors Cabozan...
Clinical Studies - Jul 17, 2020 - Jul 17, 2022
Automatically Closed
Project leader: Rothermundt Christian
Members: Aeppli Stefanie, Fischer Stefanie, Omlin Aurelius
IPSEN F-FR-60000-023
Jul 17, 2020A Phase II Multicentre, Open-Labe- Study of Cabozantinib as 2nd Line Treatment in Subjects with unresectable, locally advanced Metastatic Renal Cell Carcinoma wiht a Clear- Cell Componentn who progressed after 1st Line Treatment with Checkpoint inhib...
Clinical Studies - Jul 17, 2020 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Harder Anja, Müller Fiona
SAKK 06/17
May 22, 2018Neoadjuvant and adjuvant durvalumab in combination with neoadjuvant chemotherapy in patients with operable urothelial cancer. A Multicenter, Single-arm Phase II Trial.
Clinical Studies - May 22, 2018 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Breuss Kim, Müller Fiona
SAKK 07/17
Jan 4, 2018Nivolumab in combination with Ipilimumab in patients with metastatic renal cell carcinoma: A multicentre single-arm phase lI trial.
Clinical Studies - Jan 4, 2018 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Breuss Kim, Müller Fiona
SAKK HD 21
Jun 9, 2017Treatment optimization trial in the first-line treatment of advanced stage Hodgkin lymphoma; comparison of 6 cycles of escalated BEACOPP with 6 cycles of BrECADD.
Clinical Studies - Jun 9, 2017 - Dec 31, 2099
Ongoing
Project leader: Aeppli Stefanie
Members: Breuss Kim, Müller Fiona
A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)
Mar 26, 23Diese Studie soll die Wirksamkeit und Sicherheit von ei-nem experimentellen Medikament MK-7684A (Vibosto-limab zusammen mit Pembrolizumab) im Vergleich zu MK-3475 (Pembrolizumab) allein, bei Patienten mit im Stadium IIB–IV (Hochrisiko-Melanom) unters...
Clinical Studies - Mar 26, 23 - Dec 21, 2030
Ongoing
Project leader: Aeppli Stefanie
Members: Sennhauser Andrina